 |
|
The Efficacy and Safety of Rituximab for the Treatment of Pediatric Autoimmune Neuroinflammatory Disorders at a Single Center
Young Jun Ko, Young Kyu Shim, Woo Joong Kim, Soo Yeon Kim, Hunmin Kim, Hee Hwang, Jong-Hee Chae, Ji Eun Choi, Ki Joong Kim, Byung Chan Lim
Ann Child Neurol. 2020;28(1):30-36. Published online 2020 Jan 29 DOI: https://doi.org/10.26815/acn.2019.00290
|
|
Citations to this article as recorded by
 Rituximab for Pediatric Central Nervous System Inflammatory Disorders in Alberta, Canada
Ihor Pecuh, Jeremy Slobodan, Jennifer A. McCombe, Francois-Dominique Morneau-Jacob, Penelope Smyth, Colin Wilbur
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.2024; 51(1): 50. CrossRef The experience of anti-b-cell therapy with rituximab in children with chronic inflammatory demyelinating polyradiculoneuropathy with a description of the clinical case
N. А. Lyubimova, T. M. Pervunina, K. A. Seel, M. M. Kostik
Russian Journal for Personalized Medicine.2024; 4(4): 319. CrossRef Autoimmune Encephalitis in Children
Duriel Hardy
Pediatric Neurology.2022; 132: 56. CrossRef
|